Vivos Therapeutics (NASDAQ:VVOS) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS

by · The Cerbat Gem

Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11, Zacks reports. The business had revenue of $5.15 million during the quarter, compared to the consensus estimate of $5.63 million. Vivos Therapeutics had a negative net margin of 127.70% and a negative return on equity of 2,325.64%.

Here are the key takeaways from Vivos Therapeutics’ conference call:

  • Second-quarter revenue rose 35% to $5.2 million, driven by $1.9 million of additional service revenue from sleep testing and Vivos treatment. Gross profit increased to $3.0 million and gross margin improved to 57%.
  • Management reported several potential growth initiatives, including remote patient monitoring for an estimated 5,000–7,500 eligible CPAP patients, a planned CPAP DME program that could generate $150,000–$250,000 in monthly contribution margin, expanded EEG/insomnia services, and increased treatment-center capacity.
  • Vivos said referrals from Sleep Center of Nevada physicians to its treatment centers have increased three- to fourfold since the end of the quarter, with management expecting the resulting production to begin affecting third-quarter results. The company projects cash-flow positivity near the end of 2026 or early 2027 and significant positive EBITDA in fiscal 2027, subject to execution and reimbursement assumptions.
  • Liquidity remains a major risk: Vivos had only approximately $1.8 million in cash at June 30, used $9.2 million in operating cash during the first half, and stated that its cash is insufficient to fund the next 12 months. The company is not compliant with Nasdaq’s $2.5 million minimum stockholders’ equity requirement and may face delisting proceedings without additional equity financing and cost reductions.
  • Appliance revenue declined despite higher unit sales because of a shift toward lower-priced preformed products and away from higher-revenue CARE appliances. Meanwhile, proposed cardiology partnerships in Florida and Arizona are expected to require $800,000–$1 million of capital each, with revenue potentially beginning in the first or second quarter of 2027.

Vivos Therapeutics Price Performance

Shares of NASDAQ:VVOS traded up $0.04 during midday trading on Friday, reaching $0.34. 1,691,079 shares of the company’s stock were exchanged, compared to its average volume of 1,124,436. The stock has a market cap of $4.77 million, a price-to-earnings ratio of -0.16 and a beta of 6.22. Vivos Therapeutics has a fifty-two week low of $0.27 and a fifty-two week high of $5.12. The firm’s 50 day simple moving average is $0.46 and its two-hundred day simple moving average is $0.92.

Wall Street Analyst Weigh In

VVOS has been the subject of a number of research analyst reports. Ascendiant Capital Markets upped their price objective on shares of Vivos Therapeutics from $3.00 to $3.10 and gave the stock a “buy” rating in a research report on Thursday, June 4th. HC Wainwright cut their price target on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating for the company in a report on Friday, April 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $2.80.

Check Out Our Latest Analysis on VVOS

Hedge Funds Weigh In On Vivos Therapeutics

Several institutional investors have recently bought and sold shares of the company. DRW Securities LLC increased its stake in Vivos Therapeutics by 179.5% during the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after purchasing an additional 74,441 shares during the period. Connective Capital Management LLC acquired a new position in shares of Vivos Therapeutics in the third quarter valued at approximately $620,000. B. Riley Wealth Advisors Inc. purchased a new stake in Vivos Therapeutics during the 2nd quarter worth approximately $220,000. Finally, XTX Topco Ltd acquired a new stake in Vivos Therapeutics during the 2nd quarter worth approximately $65,000. 26.35% of the stock is owned by institutional investors and hedge funds.

About Vivos Therapeutics

(Get Free Report)

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.

See Also